Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins
- PMID: 38691205
- DOI: 10.1007/s10928-024-09922-x
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins
Abstract
Two-pore physiologically based pharmacokinetic (PBPK) modeling has demonstrated its potential in describing the pharmacokinetics (PK) of different-size proteins. However, all existing two-pore models lack either diverse proteins for validation or interspecies extrapolation. To fill the gap, here we have developed and optimized a translational two-pore PBPK model that can characterize plasma and tissue disposition of different-size proteins in mice, rats, monkeys, and humans. Datasets used for model development include more than 15 types of proteins: IgG (150 kDa), F(ab)2 (100 kDa), minibody (80 kDa), Fc-containing proteins (205, 200, 110, 105, 92, 84, 81, 65, or 60 kDa), albumin conjugate (85.7 kDa), albumin (67 kDa), Fab (50 kDa), diabody (50 kDa), scFv (27 kDa), dAb2 (23.5 kDa), proteins with an albumin-binding domain (26, 23.5, 22, 16, 14, or 13 kDa), nanobody (13 kDa), and other proteins (110, 65, or 60 kDa). The PBPK model incorporates: (i) molecular weight (MW)-dependent extravasation through large and small pores via diffusion and filtration, (ii) MW-dependent renal filtration, (iii) endosomal FcRn-mediated protection from catabolism for IgG and albumin-related modalities, and (iv) competition for FcRn binding from endogenous IgG and albumin. The finalized model can well characterize PK of most of these proteins, with area under the curve predicted within two-fold error. The model also provides insights into contribution of renal filtration and lysosomal degradation towards total elimination of proteins, and contribution of paracellular convection/diffusion and transcytosis towards extravasation. The PBPK model presented here represents a cross-modality, cross-species platform that can be used for development of novel biologics.
Keywords: Albumin; Antibody fragments; Monoclonal antibody; Physiologically based pharmacokinetic (PBPK) modeling; Protein therapeutics; Two-pore theory.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Similar articles
-
Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.J Pharmacokinet Pharmacodyn. 2019 Jun;46(3):305-318. doi: 10.1007/s10928-019-09639-2. Epub 2019 Apr 26. J Pharmacokinet Pharmacodyn. 2019. PMID: 31028591 Free PMC article.
-
Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.J Pharmacokinet Pharmacodyn. 2019 Aug;46(4):339-359. doi: 10.1007/s10928-019-09640-9. Epub 2019 May 11. J Pharmacokinet Pharmacodyn. 2019. PMID: 31079322
-
Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):67-86. doi: 10.1007/s10928-011-9232-2. Epub 2011 Dec 6. J Pharmacokinet Pharmacodyn. 2012. PMID: 22143261
-
Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins.J Pharm Sci. 2017 Sep;106(9):2270-2275. doi: 10.1016/j.xphs.2017.03.038. Epub 2017 Apr 7. J Pharm Sci. 2017. PMID: 28392453 Review.
-
Pharmacokinetic models for FcRn-mediated IgG disposition.J Biomed Biotechnol. 2012;2012:282989. doi: 10.1155/2012/282989. Epub 2012 May 14. J Biomed Biotechnol. 2012. PMID: 22665983 Free PMC article. Review.
Cited by
-
Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential.J Biol Eng. 2025 Apr 18;19(1):35. doi: 10.1186/s13036-025-00506-y. J Biol Eng. 2025. PMID: 40251669 Free PMC article.
-
Response to Letter to Editor by A. Derbalah et al.: the role of automation in enhancing reproducibility and interoperability of PBPK models.Brief Bioinform. 2024 Nov 22;26(1):bbaf060. doi: 10.1093/bib/bbaf060. Brief Bioinform. 2024. PMID: 39927860 Free PMC article. No abstract available.
-
The role of automation in enhancing reproducibility and interoperability of PBPK models.Brief Bioinform. 2024 Nov 22;26(1):bbaf053. doi: 10.1093/bib/bbaf053. Brief Bioinform. 2024. PMID: 39927861 Free PMC article. No abstract available.
-
Effect of Acute Lung Injury (ALI) Induced by Lipopolysaccharide (LPS) on the Pulmonary Pharmacokinetics of an Antibody.Antibodies (Basel). 2025 Apr 6;14(2):33. doi: 10.3390/antib14020033. Antibodies (Basel). 2025. PMID: 40265414 Free PMC article.
-
Accelerating Biologics PBPK Modelling with Automated Model Building: A Tutorial.Pharmaceutics. 2025 May 2;17(5):604. doi: 10.3390/pharmaceutics17050604. Pharmaceutics. 2025. PMID: 40430895 Free PMC article. Review.
References
-
- Zaman R et al (2019) Current strategies in extending half-lives of therapeutic proteins. J Control Release 301:176–189 - PubMed
-
- AlQahtani AD et al (2019) Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment. Biomed Pharmacother 113:108750 - PubMed
-
- Boswell CA et al (2010) Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21(12):2153–2163 - PubMed
MeSH terms
Substances
Grants and funding
- GM114179, GM146097/GM/NIGMS NIH HHS/United States
- R01CA246785, R01CA256928, and R01CA275967/CA/NCI NIH HHS/United States
- GM114179, GM146097/GM/NIGMS NIH HHS/United States
- AI138195/National Institute of Allergy and Infectious Diseases
- R01CA246785, R01CA256928, and R01CA275967/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous